Wedbush Comments on Ardelyx's Q3 Earnings (NASDAQ:ARDX)

Key Points

• Wedbush has increased its Q3 2025 earnings per share estimate for Ardelyx from ($0.05) to ($0.03), maintaining an "Outperform" rating with a price target of $14.00.
• Ardelyx reported ($0.08) EPS for its latest quarter, exceeding the consensus estimate of ($0.13), with revenues rising 23% year-over-year.
• Institutional investors and hedge funds currently own 58.92% of Ardelyx's stock, indicating strong institutional interest in the company.

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Research analysts at Wedbush boosted their Q3 2025 earnings estimates for Ardelyx in a research note issued to investors on Tuesday, August 5th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn ($0.03) per share for the quarter, up from their previous forecast of ($0.05). Wedbush currently has a "Outperform" rating and a $14.00 target price on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($0.28) EPS, FY2027 earnings at $0.41 EPS and FY2029 earnings at $0.95 EPS.

Several other equities research analysts also recently issued reports on ARDX. UBS Group set a $12.00 price objective on shares of Ardelyx in a research report on Tuesday, August 5th. Raymond James Financial restated an "outperform" rating and set a $12.00 target price (up previously from $11.00) on shares of Ardelyx in a report on Tuesday, August 5th. Piper Sandler lifted their price target on shares of Ardelyx from $8.00 to $9.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Wall Street Zen upgraded Ardelyx from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Citigroup decreased their price objective on shares of Ardelyx from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Ardelyx has an average rating of "Moderate Buy" and an average price target of $11.50.

Ardelyx Stock Up 0.3%

Shares of ARDX stock traded up $0.02 during trading hours on Thursday, hitting $5.23. 1,939,618 shares of the company were exchanged, compared to its average volume of 4,803,973. The business has a 50 day moving average of $4.16 and a two-hundred day moving average of $4.63. The company has a current ratio of 4.30, a quick ratio of 4.03 and a debt-to-equity ratio of 1.44. Ardelyx has a 52 week low of $3.21 and a 52 week high of $7.18. The company has a market capitalization of $1.26 billion, a PE ratio of -22.72 and a beta of 0.68.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.05. Ardelyx had a negative net margin of 14.60% and a negative return on equity of 36.57%. The company had revenue of $97.66 million during the quarter, compared to the consensus estimate of $82.69 million. During the same quarter in the prior year, the firm earned ($0.07) earnings per share. The firm's revenue was up 23.0% compared to the same quarter last year.

Insider Activity at Ardelyx

In other Ardelyx news, insider Laura A. Williams sold 6,421 shares of Ardelyx stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total value of $26,197.68. Following the completion of the sale, the insider owned 402,583 shares in the company, valued at $1,642,538.64. The trade was a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mike Kelliher sold 14,522 shares of Ardelyx stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total transaction of $59,249.76. Following the completion of the sale, the insider owned 282,158 shares of the company's stock, valued at $1,151,204.64. This trade represents a 4.89% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 500,000 shares of company stock worth $1,793,000 and have sold 83,477 shares worth $340,586. 4.80% of the stock is owned by corporate insiders.

Institutional Trading of Ardelyx

Several hedge funds and other institutional investors have recently bought and sold shares of ARDX. GF Fund Management CO. LTD. acquired a new stake in Ardelyx in the 4th quarter worth about $25,000. Brighton Jones LLC acquired a new stake in Ardelyx in the 2nd quarter worth about $40,000. Cyndeo Wealth Partners LLC acquired a new stake in Ardelyx in the 1st quarter worth about $49,000. Quarry LP bought a new position in Ardelyx in the 4th quarter valued at about $51,000. Finally, Rehmann Capital Advisory Group bought a new position in Ardelyx in the 4th quarter valued at about $51,000. Institutional investors and hedge funds own 58.92% of the company's stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.